A New Chapter for Artiva Biotherapeutics: Welcome, Dan Baker, M.D.!
SAN DIEGO, Jan. 29, 2025 – Get ready for some exciting changes at Artiva Biotherapeutics, Inc. (Nasdaq: ARTV)! Today, we’re thrilled to announce the appointment of a seasoned industry veteran, Dan Baker, M.D., as an independent member of our Board of Directors.
Meet Dan Baker, M.D.: A Drug Development Guru
Dr. Baker brings over two decades of invaluable experience in the pharmaceutical industry to Artiva. Currently serving as the interim Chief Development Officer of Cue Biopharma, Inc., he previously spent 19 years at Johnson & Johnson (Janssen/Centocor) (J&J), most recently holding the esteemed position of Vice President of Immunology R&D.
What This Means for Artiva Biotherapeutics
With Dan Baker’s extensive knowledge and expertise in drug development, Artiva is poised to make significant strides in the field of cell therapies for autoimmune diseases and cancers. Dr. Baker’s addition to our team will undoubtedly strengthen our commitment to delivering effective, safe, and accessible treatments to patients who need them most.
How This Impacts You
As a patient or potential investor, this appointment is fantastic news! With Dr. Baker’s guidance, Artiva Biotherapeutics is more likely to bring innovative and groundbreaking cell therapies to market, providing hope and potential relief for those suffering from devastating autoimmune diseases and cancers. Stay tuned for updates on our progress!
Global Implications
The impact of Dan Baker’s appointment extends beyond Artiva Biotherapeutics. His expertise in drug development will contribute to the broader scientific community, as the biotech industry continues to push the boundaries of cell therapies. Furthermore, his dedication to creating accessible treatments will pave the way for more equitable healthcare solutions, benefiting people worldwide.
In Conclusion
We are beyond excited to welcome Dan Baker, M.D., to the Artiva Biotherapeutics team! His wealth of knowledge and passion for developing effective and accessible treatments will undoubtedly propel us forward in our mission to revolutionize the field of cell therapies for autoimmune diseases and cancers. Stay tuned for more updates and developments as we embark on this extraordinary journey together!
- Artiva Biotherapeutics appoints Dan Baker, M.D., as an independent member of its Board of Directors
- Dr. Baker brings over two decades of drug development experience from Janssen/Centocor (J&J)
- His addition strengthens Artiva’s commitment to creating effective, safe, and accessible cell therapies
- Impact on patients: Hope for innovative and groundbreaking treatments for autoimmune diseases and cancers
- Impact on investors: Potential for significant market growth as Artiva Biotherapeutics brings new treatments to market
- Global implications: Contributes to broader scientific community and equitable healthcare solutions
